153 related articles for article (PubMed ID: 28459769)
1. Deep thoughts on lipids and cognition.
Fathallah M; Krasuski RA
Curr Opin Lipidol; 2017 Jun; 28(3):288-289. PubMed ID: 28459769
[No Abstract] [Full Text] [Related]
2. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
4. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Taylor BA; Thompson PD
Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
[TBL] [Abstract][Full Text] [Related]
5. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
7. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P
J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697
[No Abstract] [Full Text] [Related]
8. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
Filippatos TD; Kei A; Rizos CV; Elisaf MS
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
[TBL] [Abstract][Full Text] [Related]
9. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
10. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
11. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
12. [Inhibitors of PCSK9].
Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
[TBL] [Abstract][Full Text] [Related]
13. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Barthelmes J; Sudano I
Praxis (Bern 1994); 2017 Aug; 106(17):933-940. PubMed ID: 28830329
[No Abstract] [Full Text] [Related]
15. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
17. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
Sabatine MS; Giugliano RP
JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
[No Abstract] [Full Text] [Related]
18. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
19. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
Ioannidis JPA
JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
[No Abstract] [Full Text] [Related]
20. Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
Rodriguez F; Harrington RA
JAMA; 2016 Nov; 316(19):1967-1968. PubMed ID: 27838727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
